MetabolicStrong Evidence

Tirzepatide

Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist

Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.

Evidence

Strong

FDA status

FDA-approved

Source

Synthetic dual GIP/GLP-1 receptor agonist

Overview

Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.

Mechanism of Action

Activates both GIP and GLP-1 receptors for synergistic metabolic effects, enhances insulin secretion while suppressing glucagon, reduces appetite via hypothalamic pathways, improves insulin sensitivity, may affect energy use.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Weight loss (SURMOUNT trials)
  • Blood sugar control in type 2 diabetes
  • Reduced appetite and food intake
  • Improved insulin sensitivity
  • Lower HbA1c
  • Fewer breathing interruptions in sleep apnea with obesity (Zepbound)

Researched for

Includes FDA-approved uses where marked; other items are research topics, not approved uses.

Type 2 diabetesObesityMetabolic syndromeWeight managementModerate to severe obstructive sleep apnea in adults with obesity (Zepbound)

How Gabriel approaches peptides

Tirzepatide can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.

Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.

How to get tirzepatide online

Read the peptide therapy guide

Research & Evidence

Evidence Level
Strong
Studies

SURPASS and SURMOUNT trials, FDA approved

Summary

SURPASS trials support its use in type 2 diabetes (Mounjaro) and SURMOUNT trials its use for chronic weight management (Zepbound). In December 2024 FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-5 trial it produced more weight loss than semaglutide.

Safety Information

Potential Side Effects

  • •Nausea
  • •Diarrhea
  • •Vomiting
  • •Constipation
  • •Abdominal pain
  • •Injection site reactions
  • •Fatigue

Contraindications

  • Medullary thyroid carcinoma history
  • MEN 2 syndrome
  • Pregnancy
  • Breastfeeding
  • Severe GI disease

Interactions

  • ⚠Delays gastric emptying
  • ⚠May affect oral medication absorption
  • ⚠Potentiates insulin

Quick Facts

CategoryMetabolic
SourceSynthetic dual GIP/GLP-1 receptor agonist
StatusFDA-approved (Mounjaro, Zepbound). Compounded tirzepatide is not FDA-approved.